How to buy Sarepta Therapeutics stock (SRPT)

Sarepta Therapeutics is a biotechnology business based in the US. Sarepta Therapeutics shares (SRPT) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $119.47 – a decrease of 3.43% over the previous week. Sarepta Therapeutics employs 1,314 staff and has a trailing 12-month revenue of around $1.6 billion.

Our top picks for where to buy Sarepta Therapeutics stock

Buy Sarepta Therapeutics stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Sarepta Therapeutics stock price (NASDAQ: SRPT)

Use our graph to track the performance of SRPT stocks over time.

Sarepta Therapeutics shares at a glance

• Key figures

Information last updated 2024-12-19.

Latest market close	$119.47
52-week range	$91.34 - $173.25
50-day moving average more info button	$123.05
200-day moving average more info button	$129.69
Wall St. target price	$183.60
PE ratio more info button	78.0844
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$1.54

Is it a good time to buy Sarepta Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Sarepta Therapeutics price performance over time

Historical closes compared with the close of $120.25 from 2024-12-18

1 week (2024-12-13)	-2.80%
1 month (2024-11-21)	8.82%
3 months (2024-09-20)	-5.47%
6 months (2024-06-20)	-2.63%

1 year (2023-12-20)	33.18%
2 years (2022-12-20)	-5.64%
3 years (2021-12-20)	35.10%
5 years (2019-12-20)	126.17

Is Sarepta Therapeutics stock undervalued or overvalued?

Valuing Sarepta Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Sarepta Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Sarepta Therapeutics's P/E ratio

Sarepta Therapeutics's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 78x. In other words, Sarepta Therapeutics shares trade at around 78x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Sarepta Therapeutics's PEG ratio

Sarepta Therapeutics's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 159.25. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Sarepta Therapeutics's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Sarepta Therapeutics's EBITDA

Sarepta Therapeutics's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $119.7 million.

The EBITDA is a measure of a Sarepta Therapeutics's overall financial performance and is widely used to measure a its profitability.

Sarepta Therapeutics financials

Revenue TTM	$1.6 billion
Operating margin TTM	4.75%
Gross profit TTM	$-78,066,000
Return on assets TTM	1.51%
Return on equity TTM	12.27%
Profit margin	7.43%
Book value	$12.79
Market Capitalization more info button	$11.5 billion

TTM: trailing 12 months

Sarepta Therapeutics share dividends

We're not expecting Sarepta Therapeutics to pay a dividend over the next 12 months.

Have Sarepta Therapeutics's shares ever split?

Sarepta Therapeutics's shares were split on a 1:6 basis on 11 July 2012 . So if you had owned 6 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Sarepta Therapeutics shares – just the quantity. However, indirectly, the new 500% higher share price could have impacted the market appetite for Sarepta Therapeutics shares which in turn could have impacted Sarepta Therapeutics's share price.

Sarepta Therapeutics share price volatility

Over the last 12 months, Sarepta Therapeutics's shares have ranged in value from as little as $91.3439 up to $173.25. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Sarepta Therapeutics's is 0.803. This would suggest that Sarepta Therapeutics's shares are less volatile than average (for this exchange).

Sarepta Therapeutics overview

Sarepta Therapeutics, Inc. , a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

Frequently asked questions

What percentage of Sarepta Therapeutics is owned by insiders or institutions?
Currently 4.382% of Sarepta Therapeutics shares are held by insiders and 93.072% by institutions. How many people work for Sarepta Therapeutics?
Latest data suggests 1,314 work at Sarepta Therapeutics. When does the fiscal year end for Sarepta Therapeutics?
Sarepta Therapeutics's fiscal year ends in December. Where is Sarepta Therapeutics based?
Sarepta Therapeutics's address is: 215 First Street, Cambridge, MA, United States, 02142 What is Sarepta Therapeutics's ISIN number?
Sarepta Therapeutics's international securities identification number is: US8036071004 What is Sarepta Therapeutics's CUSIP number?
Sarepta Therapeutics's Committee on Uniform Securities Identification Procedures number is: 037184108